Lixte Biotechnology Holdings Inc (LIXT)
2.34
-0.05
(-2.09%)
USD |
NASDAQ |
May 24, 16:00
2.34
0.00 (0.00%)
After-Hours: 20:00
Lixte Biotechnology Holdings Enterprise Value: 5.462M for May 23, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 23, 2024 | 5.462M |
| May 22, 2024 | 5.552M |
| May 21, 2024 | 5.686M |
| May 20, 2024 | 5.372M |
| May 17, 2024 | 5.620M |
| May 16, 2024 | 5.439M |
| May 15, 2024 | 5.237M |
| May 14, 2024 | 6.024M |
| May 13, 2024 | 6.095M |
| May 10, 2024 | 5.844M |
| May 09, 2024 | 6.204M |
| May 08, 2024 | 6.305M |
| May 07, 2024 | 6.361M |
| May 06, 2024 | 6.744M |
| May 03, 2024 | 6.586M |
| May 02, 2024 | 6.568M |
| May 01, 2024 | 6.564M |
| April 30, 2024 | 6.294M |
| April 29, 2024 | 7.148M |
| April 26, 2024 | 7.418M |
| April 25, 2024 | 7.328M |
| April 24, 2024 | 7.463M |
| April 23, 2024 | 7.328M |
| April 22, 2024 | 7.621M |
| April 19, 2024 | 7.880M |
| Date | Value |
|---|---|
| April 18, 2024 | 7.623M |
| April 17, 2024 | 7.576M |
| April 16, 2024 | 7.958M |
| April 15, 2024 | 7.508M |
| April 12, 2024 | 7.913M |
| April 11, 2024 | 7.688M |
| April 10, 2024 | 7.643M |
| April 09, 2024 | 7.531M |
| April 08, 2024 | 7.531M |
| April 05, 2024 | 7.284M |
| April 04, 2024 | 7.778M |
| April 03, 2024 | 7.059M |
| April 02, 2024 | 8.408M |
| April 01, 2024 | 8.116M |
| March 28, 2024 | 6.899M |
| March 27, 2024 | 7.214M |
| March 26, 2024 | 4.369M |
| March 25, 2024 | 4.369M |
| March 22, 2024 | 4.246M |
| March 21, 2024 | 4.491M |
| March 20, 2024 | 4.492M |
| March 19, 2024 | 4.470M |
| March 18, 2024 | 4.807M |
| March 15, 2024 | 4.492M |
| March 14, 2024 | 4.402M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
2.713M
Minimum
Dec 11 2023
91.03M
Maximum
Sep 30 2019
32.66M
Average
24.30M
Median
Enterprise Value Benchmarks
| iBio Inc | 27.49M |
| PAVmed Inc | 86.84M |
| PDS Biotechnology Corp | 71.75M |
| Moleculin Biotech Inc | -4.920M |
| Syros Pharmaceuticals Inc | 70.72M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.9713M |
| Total Expenses (Quarterly) | 0.9669M |
| EPS Diluted (Quarterly) | -0.43 |
| Earnings Yield | -99.57% |